Considering that NCL is over-expressed in MDA-MB-231 human breast cancer cells and is deficient in MCF-10A normal immortalized human epidermal cells, it should be expected that uptake of the nanoprobe should preferentially localize in the breast cancer cell line. The gene discussed is NUCLEOLIN; the disease is breast cancer.